



UvA-DARE (Digital Academic Repository)

Mechanisms of arteriogenesis: from cellular adhesion to therapeutic stimulation

Höfer, I.E.

[Link to publication](#)

Citation for published version (APA):

Höfer, I. E. (2004). Mechanisms of arteriogenesis: from cellular adhesion to therapeutic stimulation

General rights

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: <http://uba.uva.nl/en/contact>, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.



LIST OF PUBLICATIONS

LIST OF PUBLICATIONS

Hoefler IE, van Royen N, Rectenwald JE, Deindl E, Hua J, Jost M, Grundmann S, Voskuil M, Ozaki CK, Piek JJ, Buschmann I.

Arteriogenesis Proceeds via ICAM-1/Mac-1-Mediated Mechanisms
Circ. Res. 2004 May 14

van Royen N, Voskuil M, Hoefler I, Jost M, de Graaf S, Hedwig F, Andert JP, Wormhoudt TA, Hua J, Hartmann S, Bode C, Buschmann I, Schaper W, van der Neut R, Piek JJ, Pals ST.

CD44 regulates arteriogenesis in mice and is differentially expressed in patients with poor and good collateralization
Circulation 2004 Apr 6;109(13):1647-52

Jost MM, Ninci F, Meder B, Kempf C, van Royen N, Hua J, Berger B, Hoefler I, Modollet M, Buschmann I.

Divergent effects of GM-CSF and TGFbeta1 on bone marrow-derived macrophage arginase-1 activity, MCP-1 expression and matrix metalloproteinase-12: a potential role during arteriogenesis
FASEB J. 2003 Dec;17(15):2281-3

Buschmann IR, Voskuil M, van Royen N, Hoefler IE, Scheffler K, Grundmann S, Hennig J, Schaper W, Bode C, Piek JJ.

Invasive and non-invasive evaluation of spontaneous arteriogenesis in a novel porcine model for peripheral arterial obstructive disease
Atherosclerosis. 2003 Mar;167(1):33-43

Deindl E, Hoefler IE, Fernandez B, Barancik M, Heil M, Striskova M, Schaper W. Involvement of the fibroblast growth factor system in adaptive and chemokine-induced arteriogenesis

Circ Res. 2003 Mar 21;92(5):561-8

van Royen N, Hoefler I, Boettinger M, Hua J, Grundmann S, Voskuil M, Bode C, Schaper W, Buschmann I, Piek JJ.

Local monocyte chemoattractant protein-1 therapy increases collateral artery formation in apolipoprotein E-deficient mice but induces systemic monocytic CD11b expression, neointimal formation and plaque progression
Circ Res. 2003 Feb 7;92(2):218-25

Voskuil M, van Royen N, Hoefler IE, Seidler R, Guth BD, Bode C, Schaper W, Piek JJ, Buschmann IR.

Modulation of collateral artery growth in a porcine hindlimb ligation model using MCP-1
Am J Physiol Heart Circ Physiol. 2003 Apr;284(4):H1422-8

van Royen N, Hoefler I, Buschmann I, Kostin S, Voskuil M, Bode C, Schaper W, Piek JJ.

Effects of local MCP-1 protein therapy on the development of the collateral circulation and atherosclerosis in Watanabe hyperlipidemic rabbits
Cardiovasc Res. 2003 Jan;57(1):178-85

- Hoefler IE, van Royen N, Rectenwald JE, Bray EJ, Abouhamze Z, Moldawer LL, Voskuil M, Piek JJ, Buschmann IR, Ozaki CK.
Direct evidence for tumor necrosis factor-alpha signalling in arteriogenesis
Circulation. 2002 Apr 9;105(14):1639-41
- van Royen N, Hoefler I, Buschmann I, Heil M, Kostin S, Deindl E, Vogel S, Korff T, Augustin H, Bode C, Piek JJ, Schaper W.
Exogenous application of transforming growth factor beta 1 stimulates arteriogenesis in the peripheral circulation
FASEB J. 2002 Mar;16(3):432-4
- Buschmann IR, Hoefler IE, van Royen N, Katzer E, Braun-Dullaues R, Heil M, Kostin S, Bode C, Schaper W.
GM-CSF: a strong arteriogenic factor acting by amplification of monocyte function
Atherosclerosis. 2001 Dec;159(2):343-56
- Deindl E, Buschmann I, Hoefler IE, Podzuweit T, Boengler K, Vogel S, van Royen N, Fernandez B, Schaper W.
Role of ischemia and of hypoxia-inducible genes in arteriogenesis after femoral artery occlusion in the rabbit
Circ Res. 2001 Oct 26;89(9):779-86
- Voskuil M, van Royen N, Hoefler I, Buschmann I, Schaper W, Piek JJ.
[Angiogenesis and arteriogenesis; the long road from concept to clinical application]
Ned Tijdschr Geneeskd. 2001 Apr 7;145(14):670-5
- Hoefler IE, van Royen N, Buschmann IR, Piek JJ, Schaper W.
Time course of arteriogenesis following femoral artery occlusion in the rabbit
Cardiovasc Res. 2001 Feb 16;49(3):609-17
- van Royen N, Piek JJ, Buschmann I, Hoefler I, Voskuil M, Schaper W.
Stimulation of arteriogenesis: a new concept for the treatment of arterial occlusive disease
Cardiovasc Res. 2001 Feb 16;49(3):543-53
- Htun P, Ito WD, Hoefler IE, Schaper J, Schaper W.
Intramyocardial infusion of FGF-1 mimics ischemic preconditioning in pig myocardium
J Mol Cell Cardiol. 1998 Apr;30(4):867-77

The first part of the document discusses the importance of maintaining accurate records of all transactions. It emphasizes that every entry should be supported by a valid receipt or invoice. This not only helps in tracking expenses but also ensures compliance with tax regulations.

In the second section, the author provides a detailed breakdown of the company's revenue streams. This includes sales from various product lines and services. The analysis shows that while one product line is currently the primary source of income, diversification into new markets is a strategic priority for the future.

The third section addresses the company's financial health and liquidity. It highlights the need for a robust cash flow management strategy to ensure that all operational needs are met. The author suggests implementing regular financial reviews to identify potential areas of concern early on.

Finally, the document concludes with recommendations for improving overall financial performance. These include investing in research and development to create innovative products, optimizing the supply chain to reduce costs, and strengthening relationships with key stakeholders.